GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cryo-Cell International Inc (AMEX:CCEL) » Definitions » Beneish M-Score
中文

Cryo-Cell International (Cryo-Cell International) Beneish M-Score : -2.59 (As of Apr. 24, 2024)


View and export this data going back to . Start your Free Trial

What is Cryo-Cell International Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.59 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Cryo-Cell International's Beneish M-Score or its related term are showing as below:

CCEL' s Beneish M-Score Range Over the Past 10 Years
Min: -4.01   Med: -2.8   Max: 0.71
Current: -2.59

During the past 13 years, the highest Beneish M-Score of Cryo-Cell International was 0.71. The lowest was -4.01. And the median was -2.80.


Cryo-Cell International Beneish M-Score Historical Data

The historical data trend for Cryo-Cell International's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryo-Cell International Beneish M-Score Chart

Cryo-Cell International Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.63 -2.90 -2.94 -2.78 -2.71

Cryo-Cell International Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.75 -2.69 -2.68 -2.71 -2.59

Competitive Comparison of Cryo-Cell International's Beneish M-Score

For the Medical Care Facilities subindustry, Cryo-Cell International's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryo-Cell International's Beneish M-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's Beneish M-Score falls into.



Cryo-Cell International Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Cryo-Cell International for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.016+0.528 * 0.9845+0.404 * 0.7849+0.892 * 1.0152+0.115 * 1.7997
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0765+4.679 * -0.017922-0.327 * 1.1037
=-2.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Feb24) TTM:Last Year (Feb23) TTM:
Total Receivables was $6.73 Mil.
Revenue was 7.852 + 7.877 + 7.87 + 7.773 = $31.37 Mil.
Gross Profit was 5.692 + 5.801 + 5.714 + 5.63 = $22.84 Mil.
Total Current Assets was $9.45 Mil.
Total Assets was $61.71 Mil.
Property, Plant and Equipment(Net PPE) was $22.56 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.42 Mil.
Selling, General, & Admin. Expense(SGA) was $17.58 Mil.
Total Current Liabilities was $19.37 Mil.
Long-Term Debt & Capital Lease Obligation was $9.16 Mil.
Net Income was 0.556 + -11.19 + 0.681 + 0.221 = $-9.73 Mil.
Non Operating Income was 0.235 + -15.845 + 0.254 + -0.188 = $-15.54 Mil.
Cash Flow from Operations was -0.357 + 3.344 + 1.942 + 1.989 = $6.92 Mil.
Total Receivables was $6.52 Mil.
Revenue was 7.824 + 7.764 + 7.681 + 7.633 = $30.90 Mil.
Gross Profit was 5.757 + 5.625 + 5.332 + 5.432 = $22.15 Mil.
Total Current Assets was $10.64 Mil.
Total Assets was $66.13 Mil.
Property, Plant and Equipment(Net PPE) was $14.95 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.79 Mil.
Selling, General, & Admin. Expense(SGA) was $16.08 Mil.
Total Current Liabilities was $18.91 Mil.
Long-Term Debt & Capital Lease Obligation was $8.79 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(6.727 / 31.372) / (6.522 / 30.902)
=0.214427 / 0.211054
=1.016

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(22.146 / 30.902) / (22.837 / 31.372)
=0.716653 / 0.727942
=0.9845

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (9.452 + 22.563) / 61.711) / (1 - (10.637 + 14.953) / 66.134)
=0.481211 / 0.613058
=0.7849

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=31.372 / 30.902
=1.0152

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.786 / (1.786 + 14.953)) / (1.422 / (1.422 + 22.563))
=0.106697 / 0.059287
=1.7997

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(17.577 / 31.372) / (16.083 / 30.902)
=0.560277 / 0.520452
=1.0765

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((9.161 + 19.37) / 61.711) / ((8.79 + 18.912) / 66.134)
=0.462332 / 0.418877
=1.1037

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-9.732 - -15.544 - 6.918) / 61.711
=-0.017922

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Cryo-Cell International has a M-score of -2.59 suggests that the company is unlikely to be a manipulator.


Cryo-Cell International Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Cryo-Cell International's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryo-Cell International (Cryo-Cell International) Business Description

Traded in Other Exchanges
Address
700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of Prepacyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. All the business activity of the group functions through the United States and it derives revenue from processing and testing fees and storage fees charged each year for storage and through sales of the Prepacyte CB units.
Executives
David Portnoy director, officer: Co-Chief Executive Officer C/O FOCUS FINANCIAL GROUP, 61 HARBOUR WAY, BAL HARBOUR FL 33154
George Gaines director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Jonathan H. Wheeler director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Brian L. Sheehy director 415 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Mark L. Portnoy director, officer: Co-Chief Executive Officer 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Harold D. Berger director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Arthur Ellis director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Mary J Nyberg 10 percent owner 455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Cdmj Nyberg Family Trust 10 percent owner 455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Jill M Taymans officer: VP, Finance, CFO
Oleg Mikulinsky officer: Chief Information Officer 700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Anthony Atala director 700 BROOKER CREEK BOULEVARD, OLDSMAR FL 34677
Scott G Christian director
Sung Won Sohn director 700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Michael W. Cho director C/O IOWA STATE UNIVERSITY, 1600 S. 16TH STREET, AMES IA 50011-1250